Showing results (51-60 of 646) with videos related to

Sort By:
Pageof 65
Hemasphere|January 25, 2020
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective StudyKonstantinos Anargyrou, Despina Fotiou, Theodoros P Vassilakopoulos, et al.
Hemasphere|January 25, 2020
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating SignalingTom Hofland, Sanne Endstra, Calum K P Gomes, et al.
Hemasphere|January 18, 2021
Bone Mineral Density Evolution and Its Determinants in Long-term Survivors of Childhood Acute Leukemia: A Leucémies Enfants Adolescents StudyMarie-Dominique Tabone, Sami Kolta, Pascal Auquier, et al.
Hemasphere|March 15, 2021
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid MalignanciesJonathan Feld, Douglas Tremblay, Mikaela Dougherty, et al.
Hemasphere|November 22, 2021
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaJulio Delgado, Irene Papadouli, Sinan B Sarac, et al.
Hemasphere|December 29, 2021
High Prevalence of Constitutional Mismatch Repair Deficiency in a Pediatric T-cell Lymphoblastic Lymphoma CohortEmma Kroeze, Dilys D Weijers, Melanie M Hagleitner, et al.
Hemasphere|October 19, 2022
CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete RemissionMohamed A Kharfan-Dabaja, Myriam Labopin, Ali Bazarbachi, et al.
Hemasphere|October 7, 2022
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple MyelomaPieter Sonneveld, Sonja Zweegman, Michele Cavo, et al.
Hemasphere|September 30, 2021
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.
Hemasphere|February 21, 2022
Correction Notice: Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A
Pageof 65